| Title | Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers - 12 years of single-centre experience in 3928 donors. | | Author(s) | Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH, Rutt C, Ehninger G | | Institution | Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany. | | Source | Blood 2009 Aug 7. | | Abstract | We present the results of PBSC mobilization, collection and follow-up from 3928 consecutive unrelated stem cell donors in a single collection centre between Jan 1996 and Jan 2008. Assessments were performed prospectively at baseline, leukapheresis, 1, 6 months and annually after PBSC donation. During follow-up side-effects were recorded by return post questionnaires. The median CD 34+ cell counts on day 5 were 67.5/microl in male and 51/microl in female donors. Bone pain and headache were the commonest side-effects of rhG-CSF. Central venous access was required for 23 donations (0.6%). Throughout the follow-up the absolute neutrophil counts were slightly below the initial baseline values, but remained within the normal range. The majority of the donors reported good or very good health. Malignancies occurred in 12 donors (0.3%), among whom were 1 case of acute myeloid leukaemia, 1 case of chronic lymphatic leukaemia and 2 cases of Hodgkin's disease. Only the incidence of Hodgkin's lymphoma differed significantly from an age-adjusted population. In conclusion, 7.5 microg/kg/d lenograstim proved to be safe and effective for mobilizing hematopoietic stem cells for allogeneic transplantation. Long-term monitoring of healthy PBSC donors remains important to guarantee the safety standards of PBSC mobilization and collection. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19666868 |
|
